EGFR and lymphangioma: After the diagnosis of LM, the 36 patients who received EGFR-TKIs achieved significantly longer iPFSLM and OSLM than patients who did not (median iPFSLM 3.9 vs. 2.7 months, p = 0.019; median OSLM 10 vs. 3.3 months, p = 0.002), and these findings are consistent with those from previous studies [5, 6, 22, 23].